Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer．
Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase 3 trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer．
复制标题
TRICOLORE 试验中共识分子亚型 (CMS) 分类分析：S-1 和伊立替康加贝伐单抗与 mFOLFOX6 或 CapeOX 加贝伐单抗作为转移性结直肠癌一线治疗的随机 3 期试验。
DOI：
--
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
1.Yuki S，Gamoh M，Denda T，Takashima A，Takahashi S，Nakamura M，Ohori H，Yamaguchi T，Kobayashi Y，Baba H，Kotake M，Amagi K，Kondo H，Shimada K，Sato A，Ishioka C，Komine K，Ouchi K，Morita S，Komatu Y
中科院分区：
文献类型：
--
作者：
Hiraide S;Takahashi M;Yoshida Y;Komine K;Ishioka C.;大内康太，高橋信，沖田啓，大槻泰史，石岡千加史;Ouchi K，Takahashi S，Ishioka C;1.Yuki S，Gamoh M，Denda T，Takashima A，Takahashi S，Nakamura M，Ohori H，Yamaguchi T，Kobayashi Y，Baba H，Kotake M，Amagi K，Kondo H，Shimada K，Sato A，Ishioka C，Komine K，Ouchi K，Morita S，Komatu Y
